Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

FLAIR Hyperintense Vessels Do Not Correlate with MRI Perfusion Deficit
Cerebrovascular Disease and Interventional Neurology
P2 - Poster Session 2 (8:00 AM-9:00 AM)
4-001

To determine whether FLAIR hyperintense vessels correlate with perfusion deficit on MRI.


 


FHV are linear serpentine hyperintensities on FLAIR MRI thought to occur from loss of normal endoluminal flow voids due to slow transit.  FHV has been previously associated with angiographic collaterals and may be associated with penumbra.  We compared presence of FHV to perfusion deficit on RAPID MRI using the FHV-ASPECTS score, previously shown to predict outcome in M1 occlusion post-thrombectomy. 



We retrospectively analyzed patients with M2 occlusion undergoing RAPID MRI from 2016-2018. We used the FHV-ASPECTs score to divide the MCA territory into 7 regions; one point was subtracted for each region containing FHV and scores ranged from 0-7.  FHV-ASPECTS score was applied to RAPID perfusion map (RAPID ASPECTs); one point was subtracted for every region containing Tmax >6.  We dichotomized FHV-ASPECTS into favorable (≤5) versus unfavorable (>5) as this cutoff has a sensitivity of 87.5% (95% CI 61.7-98.5%) and a specificity of 64.3% (95% CI 35.1-87.2%) for predicting mRS 0-2 at 90 days.   Cohen’s kappa was used to evaluate inter-rater reliability between FHV-ASPECTs score and RAPID ASPECTs score.  



49 MRIs were included.  FHV were present in 43 (87.8%) of MRIs and perfusion deficit in 38 (77.6%).  Median FHV-ASPECTS score was 4 (0-7) and median RAPID ASPECTs score was 4 (0-7).  40 (81.6%) had FHV ASPECTS ≤5 and 35 (71.4%) had RAPID ASPECTS ≤5.  Kappa for agreement between FHV ASPECTS ≤5 and RAPID ASPECTS ≤5 was nonsignificant at 0.39. 




FHV-ASPECTs score does not correlate with perfusion deficit on RAPID MRI. Likely, FHV indicate collateral viability rather than critical ischemia.  Our study was limited by the high incidence of FHV and small cohort. Further studies are needed to confirm our findings.  

Authors/Disclosures
Aidan Azher, MD (UTHealth, McGovern School of Medicine)
PRESENTER
Dr. Azher has nothing to disclose.
Katarina B. Dakay, DO No disclosure on file
Mahesh Jayaraman No disclosure on file
Ryan A McTaggart No disclosure on file
Ali Mahta, MD (Brown University) Dr. Mahta has received research support from Brown University Health.
Karen L. Furie, MD (RIH/Alpert Medical School of Brown Univ) The institution of Dr. Furie has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen/BMS. Dr. Furie has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BMJ/JNNP. The institution of Dr. Furie has received research support from NINDS.
Shadi Yaghi, MD (Hackensack Meridian Health) Dr. Yaghi has nothing to disclose.
Shawna M. Cutting, MD, FÂé¶¹´«Ã½Ó³»­ The institution of Dr. Cutting has received research support from Genentech.